TrivarX engages Emeritus Research for Stabl-Im Phase 1 study
TrivarX Limited (ASX: TRI) has formally engaged Emeritus Research to conduct its planned Phase 1 healthy volunteer study of Stabl-Im at Emeritus’ Melbourne clinical research facility. The appointment secures the clinical site for the study.
First participant enrolment remains on track for Q1 CY2027, with initial study results anticipated in Q2 CY2027, subject to ethics, regulatory and operational requirements.
The engagement follows TrivarX’s recent appointment of Syntro Health for investigational product formulation. With the clinical site and product preparation partner both engaged, the company said it has key delivery partners in place.
Dr Danielle Meyrick, Chief Executive Officer
“Engaging Emeritus Research is a concrete step forward for our Stabl-Im platform, and as part of their engagement we have secured an experienced clinical research team and the required infrastructure to deliver our planned healthy volunteer study.”
Why Emeritus was selected
TrivarX selected Emeritus for three capabilities:
- Established clinical trial infrastructure
- Experienced research personnel
- Participant recruitment capabilities
Emeritus and its affiliates form an Australian clinical research site network with over 25 years of experience. They have conducted clinical trials across a broad range of therapeutic areas.
The Melbourne facility combines dedicated clinical research infrastructure with research-dedicated clinicians and disciplined processes and procedures. These are intended to ensure efficient, compliant trial execution while optimising participant recruitment rate and retention.
Dr Meyrick joined as CEO on 1 June 2026 from senior roles at Telix Pharmaceuticals and ITM Isotopes Technologies Munich, and management has said the Phase 1 study is funded without additional capital.
When big ASX news breaks, our subscribers know first
What Stabl-Im and the Phase 1 study aim to show
Stabl-Im is TrivarX’s stable isotope-based imaging development platform. It aims to improve the detection and characterisation of cancer, with an initial focus on brain tumours and brain metastases.
The approach uses controlled enrichment with deuterium, a non-radioactive stable isotope of hydrogen. The aim is to investigate whether metabolic differences between healthy and cancer tissue can be detected using magnetic resonance imaging (MRI).
The planned Phase 1 study will evaluate the following in healthy volunteers:
- Safety of controlled systemic deuterium enrichment
- Tolerability of controlled systemic deuterium enrichment
- Pharmacokinetics, including how enrichment develops and washes out over time
The study is designed to establish a clinical data foundation for subsequent development. By characterising enrichment and its variability between participants, the findings will inform the dosing regimen for future studies and streamline clinical development across the intended and potential applications.
Delivery partners and preparations in progress
Three workstreams are progressing towards the targeted first participant enrolment in Q1 CY2027:
- Clinical site preparations
- Investigational product preparation
- Specialist analytical methodology development
Syntro Health, an Australian pharmaceutical manufacturing specialist, is handling investigational product formulation activities.
The Syntro Health formulation work runs in parallel with analytical method work-up, dosing protocols and site selection, though contract value, fees and the formulation completion timeline were not disclosed.
| Partner | Role | Status |
|---|---|---|
| Emeritus Research | Phase 1 clinical site, Melbourne | Formally engaged |
| Syntro Health | Investigational product formulation | Recently engaged |
What happens next for TrivarX
With the clinical trial site now selected and formally engaged, the company has outlined the following steps:
- TrivarX will work closely with Emeritus to finalise site-specific study preparations, ethics and regulatory submissions, recruitment planning and operational readiness ahead of study commencement.
- First participant enrolment is targeted for Q1 CY2027, supported by parallel investigational product preparation and specialist analytical methodology development.
- Initial study results are anticipated in Q2 CY2027, subject to completion of the remaining ethics, regulatory and operational requirements.
The findings will guide subsequent clinical development activities and the company’s evaluation of Stabl-Im’s potential in oncology imaging.
Want Alerts Like This on the Biotech Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist today.